491000 · KOSDAQ · ₩491000 · 리브스메드
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−57.8% from the high
₩27,100Today: ₩39,700 – ₩43,575₩95,900
Returns
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
−7.3% on Oct 29, 2026.
LivsMed received a Commissioner's award from the Korean Intellectual Property Office at its Corporate Intellectual Property Awards. The award recognized the company's patent competitiveness.
AI summary of the news and filings linked. It can be wrong; check them.
Possible reasons, not certainties. Not financial advice.
Signals describe activity, not recommendations. Not financial advice.
Estimated leveraged-ETF rebalance on Oct 29: sell ₩324M at the close (2.7% of 20-day average trading value)
On its 36 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 13.0% of trading value and pointed the same way 26 of 36 times.
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
Held by 11 funds.
Estimated from the funds' index or underlying stock.
LivsMed (리브스메드, KRX: 491000) is listed on KOSDAQ, in the Medical & precision devices sector. The company develops, manufactures and sells laparoscopic surgical instruments used in minimally invasive surgery. Its shares closed at ₩40,450 on Oct 29, 2026, down 7.33% on the day, giving it a market value of ₩1T.
The company develops, manufactures and sells laparoscopic surgical instruments used in minimally invasive surgery. Its main products include the ArtiSential multi-joint laparoscopic instrument, which bends up to 90 degrees in each direction, and the ArtiSeal multi-joint vascular sealer. It is also developing a surgical stapler, a 3D4K laparoscopic camera system and a surgical robot, aiming to provide a total minimally invasive surgery solution, and has obtained regulatory approvals in Korea, the United States, Europe and Japan.
Written by AI from the company's latest annual report.
Predicted impact: Low
Intellectual property award recognition; routine and small with no financial impact.
Predicted impact: Low
Predicted impact: Low
Pursuit of US and Japan approvals for surgical robot; regulatory timing uncertain, no size given.
Titles in Korean until English translations are added.
Also known as: LivsMed / 리브스메드 / 491000 / KRX:491000
Source: KRX statistical information